CANCER BUZZ TV

The high cost associated with cancer diagnosis, treatment, and survivorship makes the burden of financial toxicity an unavoidable reality for many patients—and makes financial navigators central to the delivery of high-quality cancer care. In this vodcast episode, CANCER BUZZ speaks with Heather Simpson, BCPA, patient financial navigator lead, who shares her experience using the ACCC Financial Advocacy Network’s financial advocacy services guidelines assessment tool to pinpoint financial navigation challenges within her cancer program.

Expanding access to clinical trials in community oncology settings is essential to improving diversity, equity, and inclusion in cancer research. In this episode, CANCER BUZZ speaks with clinical research coordinator, Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP, whose cancer center recently participated in a foundational oncology clinical trials course, developed by ACCC and the Association of Clinical Research Professionals (ACRP) to help cancer programs expand availability of trials to traditionally underserved communities. Oladipupo shares how this training prepared their center for the challenges of a growing research program, the progress they’ve made, and the pivotal role of clinical research coordinators in expanding research programs and improving patient access to clinical trials.

Bladder cancer remains a prevalent disease with significant disparities in care, particularly in underserved populations. To address this, ACCC launched a national quality improvement initiative in three phases: 1. assessment and preparation, 2. action plan implementation, and 3. monitoring for continuous improvement. Dr. Samuel Washington, from the University of California, San Francisco, discussed the initiative’s early findings, highlighting site-specific approaches.

In this episode, CANCER BUZZ speaks with Julie Ryan Wolf, PhD, MPH and C.J.G. (Corina) van den Hurk, PhD, the chair and vice chair of the Oncodermatology Study Group at the Multinational Association of Supportive Care in Cancer (MASCC) about common oncodermatological toxicities including radiation dermatitis, hair loss, and nail changes unique to EGFR-inhibitors. Also discussed are strategies to increase provider collaboration to intervene at an early stage to improve quality of life for patients receiving cancer treatment.

In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor of hematology and medical oncology at Winship Cancer Institute of Emory University, to discuss the impact of bispecific antibodies on cancer treatment outcomes, and the challenges and opportunities of integrating this innovative approach into community oncology practices.

In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-basedmanagement of treatment-related adverse events can serve this patient population.

In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.

In this episode, CANCER BUZZ speaks with Karen Fancher, PharmD, BCOP, clinical pharmacy specialist in oncology at University of Pittsburgh – Passavant Hospital, and Victoria Nachar, PharmD, BCOP, clinical pharmacist specialist in ambulatory hematology and adjunct clinical instructor at the University of Michigan, about strategies to address common adverse events experienced by patients with mantle cell lymphoma.

In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor at Emory University School of Medicine in Atlanta, Georgia, about fostering trust, rapport, and collaboration in the patient-provider relationship.

In this episode, CANCER BUZZ speaks with David Sallman, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center, and Karley Trautman, DNP, ANP-BC, AGACNP-BC, senior instructor of Medical Oncology at Highlands Ranch Cancer Center, to discuss best practices in the management of anemia in low-risk MDS patients.

Gain insights on reshaping multidisciplinary cancer care team workflows to enable laboratory professionals to improve biomarker testing efficiency.

In this episode, CANCER BUZZ speaks with Steven Gilmore, PharmD, BCOP, Senior Manager of Clinical Content in Pharmacy and Clinical Programs with McKesson Specialty Health, and Christopher Benton, MD, hematologist and medical oncologist at Rocky Mountain Cancer Centers, to review key considerations and emerging trends for the treatment of anemia in the low-risk MDS population.

In this episode, CANCER BUZZ TV speaks with Tom Lycan, DO, MHS, assistant professor of Hematology & Oncology at the Wake Forest School of Medicine, about a practical tool that can provide a care plan roadmap for providers and patients to mitigate precision medicine disparities.

In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, director, Bone Marrow Failure and MDS Program, Johns Hopkins University School of Medicine in Baltimore, Maryland; Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, clinical oncology pharmacy manager, Atrium Health Levine Cancer in Charlotte, North Carolina; and David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center in Tampa, Florida. Their discussion elucidates an array of patient-centered approaches, touches on social determinants of health, and highlights collaborative measures to support care coordination in the management of anemia in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.

In this episode, CANCER BUZZ speaks with Raymond Liu, MD, director of research of Hematology-Oncology in Kaiser Permanente Northern California, director of cancer survivorship in Kaiser Permanente San Francisco, and assistant clinical professor at UCSF, who shares how successful implementation of the 4R Oncology® model empowers patients and clinicians and coheres care teams.

Maintenance therapy for patients with acute myeloid leukemia, particularly those who are ineligible for transplant, can be critical to treatment outcomes and quality of life for patients. In this episode, CANCER BUZZ speaks with Thomas LeBlanc, MD, hematologic oncologist, associate professor of Medicine, and associate professor in Population Health Sciences at Duke Cancer Institute, about the importance of keeping patients with acute myeloid leukemia in first remission as long as possible through maintenance therapy.

Coordination of care for patients diagnosed with acute myeloid leukemia, particularly those who are ineligible for transplant, can impact access to specialist care, clinical trials, and cancer programs with advanced capabilities to treat patients with acute myeloid leukemia.

In this episode, CANCER BUZZ speaks with Farrukh T. Awan, MD, MS, professor of Internal Medicine and director of Lymphoid Malignancies at the Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, about their approach to addressing regional barriers to improve care for patients with chronic lymphocytic leukemia.

Personalizing care goals to account for a patient’s values, preferences, or circumstances can make a significant difference in shared decision-making and treatment planning. In this episode, CANCER BUZZ speaks with Melissa Kah Poh Loh, MBBCh, BAO, assistant professor of Geriatric Hematology and Oncology at the University of Rochester Medical Center’s Wilmot Cancer Institute about strategies to optimize critical conversations with patients with acute myeloid leukemia.

Significant declines in the screening, diagnosis, and treatment of patients with small cell lung cancer have increased challenges that impact patient care. Many patients with small cell lung cancer have a high symptom burden, poor prognosis, adherence challenges due to treatment-related adverse events, stigmatization, and emotional distress. The team at Atrium Health’s Levine Cancer Institute is testing supportive care options with the goal of meeting the needs of all their patients.

While there are many factors why patients with acute myeloid leukemia are ineligible for allogeneic stem cell transplant, such as age, financial hurdles, or other comorbidities, these factors are often compounded by social determinants of health, which can act as a significant barrier to consolidation therapy and long-term remission for these patients. In this episode, CANCER BUZZ speaks with Keri Maher, DO, Director of the Acute Leukemia Program, and assistant professor at Virginia Commonwealth University’s Massey Cancer Center about strategies to address these disparities and optimize care and treatment options for patients with acute myeloid leukemia who do not receive a transplant.

Learn how recent guideline and treatment options by the National Comprehensive Cancer Network (NCCN) can optimize care for patients with MPNs.

Hear suggestions for how to reduce financial hurdles and increase access to cancer diagnostics.

As cancer programs seek new ways to improve coordination of molecular testing, hear how precision medicine stewards can streamline testing processes to improve efficiency and improve the patient experience.

As myeloproliferativeneoplasms (MPNs) carry a significant symptom burden and oftentimes can requirelifelong care coordination and close monitoring, hear how a strongmultidisciplinary approach can impact shared decision-making and patientengagement.

CANCER BUZZ speaks with Srdan Verstovsek, MD, PhD, about when to begin therapeutic care for myeloproliferative neoplasms (MPNs) and the urgency of treatment.

Multidisciplinary care coordination is especially important with aggressive cases of SCLC, as there may be several unique challenges to be addressed. Watch now!

Learn about a nurse’s role in care planning, and engaging patients in education, and shared decision making for treatment goals and planning.

Hear why community practices need to monitor symptoms carefully and about a new tool that can help assess symptoms more accurately and help care teams form treatment plans.